Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline Review, H1 2018

Global Markets Direct’s, ‘Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline Review, H1 2018’, provides an overview of the Methicillin-Resistant Staphylococcus aureus (MRSA) Infections pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Methicillin-Resistant Staphylococcus aureus (MRSA) Infections, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Methicillin-Resistant Staphylococcus aureus (MRSA) Infections and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Methicillin-Resistant Staphylococcus aureus (MRSA) Infections

- The report reviews pipeline therapeutics for Methicillin-Resistant Staphylococcus aureus (MRSA) Infections by companies and universities/research institutes based on information derived from company and industry-specific sources

- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

- The report reviews key players involved Methicillin-Resistant Staphylococcus aureus (MRSA) Infections therapeutics and enlists all their major and minor projects

- The report assesses Methicillin-Resistant Staphylococcus aureus (MRSA) Infections therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

- The report summarizes all the dormant and discontinued pipeline projects

- The report reviews latest news related to pipeline therapeutics for Methicillin-Resistant Staphylococcus aureus (MRSA) Infections

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Methicillin-Resistant Staphylococcus aureus (MRSA) Infections

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Methicillin-Resistant Staphylococcus aureus (MRSA) Infections pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

AbbVie Inc

Absynth Biologics Ltd

Actelion Pharmaceuticals Ltd

Adenium Biotech ApS

Alchemia Ltd

Allergan Plc

AmpliPhi Biosciences Corp

Antibiotx ApS

Aphios Corp

Aridis Pharmaceuticals LLC ...

AbbVie Inc

Absynth Biologics Ltd

Actelion Pharmaceuticals Ltd

Adenium Biotech ApS

Alchemia Ltd

Allergan Plc

AmpliPhi Biosciences Corp

Antibiotx ApS

Aphios Corp

Aridis Pharmaceuticals LLC

Atriva Therapeutics GmbH

Bavarian Nordic A/S

Bharat Biotech Ltd

C3J Therapeutics Inc

Cadila Pharmaceuticals Ltd

Citius Pharmaceuticals Inc

ContraFect Corp

Crestone Inc

CrystalGenomics Inc

Daiichi Sankyo Co Ltd

Debiopharm International SA

DesignMedix Inc

Destiny Pharma Ltd

Emergent BioSolutions Inc

GangaGen Inc

Helix BioMedix Inc

Helperby Therapeutics Group Ltd

Hsiri Therapeutics LLC

Ildong Pharmaceutical Co Ltd

Insmed Inc

Instituto Biomar SA

iNtRON Biotechnology Inc

ioGenetics Inc

KBP BioSciences Co Ltd

Kyorin Pharmaceutical Co Ltd

Lakewood-Amedex Inc

Lead Discovery Center GmbH

LegoChem Biosciences Inc

Madam Therapeutics BV

Meiji Seika Pharma Co Ltd

Melinta Therapeutics Inc

Merck & Co Inc

Microbiotix Inc

MicuRx Pharmaceuticals Inc

Nabriva Therapeutics plc

Nemus Bioscience Inc

Novabiotics Ltd

NovaDigm Therapeutics Inc

Novalex Therapeutics Inc

Novan Inc

NovoBiotic Pharmaceuticals LLC

Oragenics Inc

Ovensa Inc

Oxford Drug Design Ltd

Pfizer Inc

Phico Therapeutics Ltd

PolyPid Ltd

Prommune Inc

Recce Ltd

Savara Inc

Sealife PHARMA GMBH

Sorrento Therapeutics Inc

Taejoon Pharm Co Ltd

TAXIS Pharmaceuticals Inc

Telephus Medical LLC

Tetraphase Pharmaceuticals Inc

Therapeutic Systems Research Laboratories Inc

Theravance Biopharma Inc

Trellis Bioscience Inc

Valevia UK Ltd

Venus Medicine Research Center

VLP Biotech Inc

Wockhardt Ltd

XBiotech Inc

Yungjin Pharm Co Ltd

Table of Contents

Table of Contents

Table of Contents 2

Introduction 6

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Overview 7

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Therapeutics Development ...

Table of Contents

Table of Contents 2

Introduction 6

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Overview 7

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Therapeutics Development 8

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Therapeutics Assessment 38

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Companies Involved in Therapeutics Development 48

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Drug Profiles 82

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Dormant Projects 346

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Discontinued Products 358

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Product Development Milestones 359

Appendix 370

List of Tables

List of Tables

Number of Products under Development for Methicillin-Resistant Staphylococcus aureus (MRSA) Infections, H1 2018

Number of Products under Development by Companies, H1 2018 ...

List of Tables

Number of Products under Development for Methicillin-Resistant Staphylococcus aureus (MRSA) Infections, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products under Development by Universities/Institutes, H1 2018

Products under Development by Companies, H1 2018

Products under Development by Universities/Institutes, H1 2018

Number of Products by Stage and Target, H1 2018

Number of Products by Stage and Mechanism of Action, H1 2018

Number of Products by Stage and Route of Administration, H1 2018

Number of Products by Stage and Molecule Type, H1 2018

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by AbbVie Inc, H1 2018

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Absynth Biologics Ltd, H1 2018

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Actelion Pharmaceuticals Ltd, H1 2018

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Adenium Biotech ApS, H1 2018

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Alchemia Ltd, H1 2018

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Allergan Plc, H1 2018

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by AmpliPhi Biosciences Corp, H1 2018

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Antibiotx ApS, H1 2018

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Aphios Corp, H1 2018

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Aridis Pharmaceuticals LLC, H1 2018

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Atriva Therapeutics GmbH, H1 2018

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Bavarian Nordic A/S, H1 2018

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Bharat Biotech Ltd, H1 2018

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by C3J Therapeutics Inc, H1 2018

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Cadila Pharmaceuticals Ltd, H1 2018

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Citius Pharmaceuticals Inc, H1 2018

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by ContraFect Corp, H1 2018

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Crestone Inc, H1 2018

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by CrystalGenomics Inc, H1 2018

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Daiichi Sankyo Co Ltd, H1 2018

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Debiopharm International SA, H1 2018

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by DesignMedix Inc, H1 2018

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Destiny Pharma Ltd, H1 2018

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Emergent BioSolutions Inc, H1 2018

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by GangaGen Inc, H1 2018

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Helix BioMedix Inc, H1 2018

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Helperby Therapeutics Group Ltd, H1 2018

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Hsiri Therapeutics LLC, H1 2018

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Ildong Pharmaceutical Co Ltd, H1 2018

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Insmed Inc, H1 2018

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Instituto Biomar SA, H1 2018

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by iNtRON Biotechnology Inc, H1 2018

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by ioGenetics Inc, H1 2018

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by KBP BioSciences Co Ltd, H1 2018

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Kyorin Pharmaceutical Co Ltd, H1 2018

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Lakewood-Amedex Inc, H1 2018

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Lead Discovery Center GmbH, H1 2018

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by LegoChem Biosciences Inc, H1 2018

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Madam Therapeutics BV, H1 2018

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Meiji Seika Pharma Co Ltd, H1 2018

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Melinta Therapeutics Inc, H1 2018

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Merck & Co Inc, H1 2018

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Microbiotix Inc, H1 2018

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by MicuRx Pharmaceuticals Inc, H1 2018

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Nabriva Therapeutics plc, H1 2018

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Nemus Bioscience Inc, H1 2018

List of Figures

List of Figures

Number of Products under Development for Methicillin-Resistant Staphylococcus aureus (MRSA) Infections, H1 2018

Number of Products under Development by Companies, H1 2018 ...

List of Figures

Number of Products under Development for Methicillin-Resistant Staphylococcus aureus (MRSA) Infections, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products under Development by Universities/Institutes, H1 2018

Number of Products by Top 10 Targets, H1 2018

Number of Products by Stage and Top 10 Targets, H1 2018

Number of Products by Top 10 Mechanism of Actions, H1 2018

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2018

Number of Products by Routes of Administration, H1 2018

Number of Products by Stage and Routes of Administration, H1 2018

Number of Products by Top 10 Molecule Types, H1 2018

Number of Products by Stage and Top 10 Molecule Types, H1 2018

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports